Key Insights

Highlights

Success Rate

96% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

2.8%

2 terminated out of 71 trials

Success Rate

95.6%

+9.0% vs benchmark

Late-Stage Pipeline

28%

20 trials in Phase 3/4

Results Transparency

7%

3 of 43 completed with results

Key Signals

3 with results96% success

Data Visualizations

Phase Distribution

46Total
Not Applicable (12)
Early P 1 (1)
P 1 (7)
P 2 (6)
P 3 (7)
P 4 (13)

Trial Status

Completed43
Unknown16
Not Yet Recruiting5
Recruiting4
Terminated2
Suspended1

Trial Success Rate

95.6%

Benchmark: 86.5%

Based on 43 completed trials

Clinical Trials (71)

Showing 20 of 20 trials
NCT07631065Phase 4Not Yet RecruitingPrimary

Phase 4 Study of Sto M Tab. in Acute or Chronic Gastritis

NCT07624422Phase 4Not Yet Recruiting

Vonoprazan High-Dose Dual VS Levofloxacin Concomitant

NCT07385248Phase 1Not Yet RecruitingPrimary

A Clinical Trial to Assess the Pharmacokinetics and Safety of AD-229 Compared to AD-2291 in Healthy Adults

NCT07378540Completed

Evaluation of Microbial Status in Gastritis Patients in Different Periodontal Conditions

NCT04306939Suspended

Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

NCT06981819Completed

Establishment and Effectiveness Evaluation of a Training System for Confocal Laser Endomicroscopy

NCT07139366Phase 4RecruitingPrimary

Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment

NCT07088744Not Yet Recruiting

Comparison of the Sensitivity of pCLE and Pathological Biopsy Before ESD

NCT06948487RecruitingPrimary

Efficacy and Safety of FEXUCLUE Tab. In Patients With Acute or Chronic Gastritis

NCT06848400Not ApplicableRecruiting

Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios

NCT07032961RecruitingPrimary

A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies Screening

NCT05742568Phase 4CompletedPrimary

Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology

NCT06935955Not Yet RecruitingPrimary

Helicobacter Pylori Gastritis and Its Relation to Metabolic Syndrome Components

NCT06576882Phase 3Completed

7 Days vs. 14 Days of Vonoprazan-based Triple Therapy for H. Pylori Eradication

NCT06668506CompletedPrimary

To Evaluate Improvement Effect of Subjective Symptoms of Mucotra SR Tablet in Patients With Gastritis

NCT05072938Phase 4CompletedPrimary

Clinical Trial to Compare Rebamipide/Nizatidine Combination Therapy With Nizatidine Monotherapy in Patients With Gastritis

NCT05579444Terminated

Systems Biology of Gastrointestinal and Related Diseases

NCT04724291Not ApplicableCompleted

MAGNET (Magnetically Controlled Capsule for Assessment of Gastric Mucosa in Symptomatic Patients)

NCT04672018Phase 2CompletedPrimary

Efficacy and Safety of Houtou Jianweiling Tablet in the Treatment of Chronic Non-Atrophic Gastritis

NCT02175186Phase 4CompletedPrimary

Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

Scroll to load more

Research Network

Activity Timeline